Newsstand | Aplastic Anemia and MDS International Foundation

Newsstand

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Multiple Studies Help Define New Biomarkers for Myelodysplastic Syndromes

Originally Published: 09/11/2018
According to a story from Medpage Today, three recent research studies have managed to reveal new biomarkers for myelodysplastic syndromes. Biomarkers are a crucial factor for understanding a medical condition or disease. They can serve as critical diagnostic tools when signs and symptoms are too vague for doctors to make an accurate determination.In addition, biomarkers can help doctors make critical decisions about how to administer care.

Dr. Komrokji on the Changing Landscape of AML

Originally Published: 09/10/2018
Rami S. Komrokji, MD, principal investigator, MDS Research Consortium, Aplastic Anemia and MDS International Foundation, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses the changing landscape of acute myeloid leukemia (AML).  (video format)

Leukemia Research: Acute Myeloid Leukemia Researcher targets frequent culprit in blood cancers

Originally Published: 09/04/2018
Ramesh Balusu, Ph.D., one of our researchers at The University of Kansas Cancer Center, is working to uncover what happens behind the scenes leading to the development of certain types of blood cancers like acute myeloid leukemia. 

CHIP – A Promising Genetic Discovery for MDS, AML and Cardiovascular Disease

Originally Published: 08/30/2018
Thanks to recent advances in genetic analysis techniques, scientists studying how genetic mutations impact the progression of bone marrow failure have discovered how these mutations may also affect cardiovascular disease.  An example of this is new research that has shown how a buildup of mutated stem cells in the bone marrow may be a risk factor not only for hematologic malignancy but also heart disease. This condition is known as clonal hematopoiesis of indeterminate potential, or CHIP. The key word in understanding the significance of CHIP is “indeterminate,” because researchers are still...

Phase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation

Originally Published: 08/30/2018
This multicenter study, which began in 2013, was led by Dr. Eytan Stein at Memorial Sloan Kettering Cancer Center in New York, NY. Its purpose was to evaluate the safety and efficacy of orally administered AG-221 (Enasidenib) in subjects with advanced Acute Myeloid Leukemia (AML) that harbor an IDH2 mutation. As a result of this phase I/II study, and Celgene’s request for priority review status, the FDA approved of AG-221 in August, 2017 for patients with relapse and/or refractory AML with an IDH2 mutation. During the study, researchers discovered that AG-221 also had a positive effect on...

Let’s Go FISH-ing!

Originally Published: 08/30/2018
The recent emergence of targeted therapies has revolutionized the understanding and treatment of some bone marrow failure diseases, particularly myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).  Targeted therapies are treatments that work by targeting specific genes or proteins to help stop cancer from progressing. It is different from chemotherapy, which affects all fast-growing cells at once. These therapies are made possible due to new medical technologies and diagnostic testing methods such as FISH. What is FISH? Fluorescence in situ hybridization (also known as FISH) is...

How Bone Marrow and Stem Cell Transplants Work

Originally Published: 08/29/2018
If you or a loved one will be having a bone marrow transplant or donating stem cells, what does it entail? What are the different types of bone marrow transplants and what is the experience like for both the donor and recipient?

New Tool Helps Patients With Myelofibrosis Time Stem Cell Transplantation for Better Outcomes

Originally Published: 08/17/2018
An allogeneic stem cell transplant (ASCT) is the only treatment that has the potential to cure myelofibrosis (MF), one of the three main types of myeloproliferative neoplasms (MPN); however, a stem cell transplant comes with risks — some potentially life-threatening. Fortunately, there is a new tool that can help with these potential concerns.

Immunotherapies for the treatment of AML

Originally Published: 08/14/2018
Description: Gemtuzumab ozogamicin is a monoclonal antibody drug for the treatment of acute myeloid leukemia (AML). This drug uses a different strategy to classical chemotherapeutic agents, and the development of other similar drugs is expected to drastically improve the outcomes of patients with AML. In this interview, Chrisoph Röllig, MD, from the University Hospital Carl Gustav Carus, Dresden, Germany, also discusses treatments that have recently received FDA approval, such as CPX-351, a liposomal formulation of cytarabine and daunorubicin that has been approved for the treatment of...

MDS Update, July 2018

Originally Published: 07/25/2018